Stryker plunges 12% Q3 results, guidance disappoint
Stryker (NYSE:SYK) reported Q3 adjusted EPS of $3.52, missing estimates by $0.03, and revenue of $6.5B, below the $6.62B consensus. The company lowered its 2026 adjusted EPS guidance to $14.80-$14.90, below the $14.95 consensus. Shares fell 12% post-announcement. Organic sales grew 7.7% YoY, with MedSurg and Neurotechnology up 9.2% and Orthopaedics up 5.7%.
How this was made
The 30-second read
Why it matters
The key trading driver is the combination of Q3 adjusted EPS and revenue below consensus and a FY 2026 guidance midpoint below consensus, which the market responded to with a sharp share drop.
Market read
This is a direct earnings-and-guidance catalyst for SYK, with explicit consensus deltas and a large same-day decline.
What to watch
The guidance range is narrow ($14.80-$14.90) and includes management’s expectation of solid Q4 performance; traders should separate near-term estimate risk from longer-cycle demand and margin trajectory.
Background
Stryker is a large medtech company with MedSurg and Neurotechnology plus Orthopaedics segments; this report updates Q3 performance and full-year 2026 adjusted EPS guidance.
Ticker impact
Stryker reported Q3 adjusted EPS $3.52 vs $3.55 consensus and guided FY 2026 adjusted EPS to $14.80-$14.90 vs $14.95, shares fell 12%.
Likely further pressure or elevated volatility as traders weigh the guidance shortfall versus the company’s stated Q4 momentum.
The article provides the company’s own Q3 results, explicit consensus comparisons, and a lower FY guidance midpoint, alongside a large same-day decline.
Market effects
Medical technology peers may see read-across selling if investors interpret the miss as demand or margin pressure rather than execution noise.
Limited direct regional spillover; primarily a single-name repricing within US healthcare/medtech.
Moderate, as medtech is globally diversified but the catalyst is company-specific guidance and results.
Counterpoint
The company still reports 7.7% organic sales growth and expanding adjusted operating margin, so the selloff may overreact to small EPS/revenue misses versus the broader fundamentals.
Key entities
- companyStryker Corporation
Reported Q3 adjusted EPS and revenue below consensus and lowered FY 2026 adjusted EPS midpoint versus analyst expectations.
